Related content

Pharmacogenomics of Multiple Sclerosis: Current Status and Potential Applications

By  

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 8, Iss. 4, 2010-12 ,pp. : 273-279

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacogenetics and pharmacogenomics of sexual dysfunction: current status, gaps and potential applications

By Abdel-Hamid Ibrahim A   Andersson Karl-Erik  

Pharmacogenomics, Vol. 10, Iss. 10, 2009-10 ,pp. : 1625-1644

Future Medicine

Access to resources Recommend Favorite

Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations

By Ellis Kyle J   Stouffer George A   McLeod Howard L   Lee Craig R  

Pharmacogenomics, Vol. 10, Iss. 11, 2009-11 ,pp. : 1799-1817

Future Medicine

Access to resources Recommend Favorite

Beyond CYP2C19 – A New Chapter in Clopidogrel Pharmacogenomics

By  

JOURNAL OF PHARMACY PRACTICE AND RESEARCH, Vol. 41, Iss. 1, 2011-03 ,pp. : 14-16

John Wiley & Sons Inc

Access to resources Recommend Favorite

The current and future state of pharmacogenomics medical education in the USA

By Nickola Tracey J   Green James S   Harralson Arthur F   O’Brien Travis J  

Pharmacogenomics, Vol. 13, Iss. 12, 2012-09 ,pp. : 1419-1425

Future Medicine

Access to resources Recommend Favorite